Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 738-743 , December 2009

Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma

  • Eirini Katodritou

      Affiliations

    • Department of Hematology, Theagenion Cancer Center, Thessaloniki, Greece
    • Greek Myeloma Study Group, Greek Society of Hematology, Greece
    • ,
  • Meletios A. Dimopoulos

      Affiliations

    • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    • Greek Myeloma Study Group, Greek Society of Hematology, Greece
    • ,
  • Konstantinos Zervas

      Affiliations

    • Department of Hematology, Theagenion Cancer Center, Thessaloniki, Greece
    • Greek Myeloma Study Group, Greek Society of Hematology, Greece
    • ,
  • Evangelos Terpos

      Affiliations

    • Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    • Greek Myeloma Study Group, Greek Society of Hematology, Greece
    • Corresponding Author InformationCorresponding author. Addresses: Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece; 5 Marathonomahon street, 14572, Athens, Greece. Tel.: +30 210 7463803; fax: +30 210 7464676.

Received 17 May 2009 ,Revised 4 August 2009 ,Accepted 6 August 2009.

References 

  1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29–40
  2. Harper P, Littlewood T. Anemia of cancer: impact on patient fatigue and long-term outcome. Oncology. 2005;69:2–7
  3. Moullet I, Salles G, Ketterer N, et al. Frequency and significance of anaemia in non-Hodgkin’s lymphoma patients. Ann Oncol. 1998;9:1109–1115
  4. Meyer RM, Browman GP, Samosh ML, et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:2386–2393
  5. Birgegard G, Gascon P, Ludwig H, et al. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. European J Haematol. 2006;77:378–386
  6. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma. 2003;4:23–29
  7. Ludwig H, Rai K, Blade J, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J. 2002;3:121–130
  8. Goodnough L. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol. 2007;35:167–172
  9. Weiss G, Goodnough L. Anemia of chronic disease. N Eng J Med. 2005;352:1011–1023
  10. Sharma S, Nemeth E, Chen YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14:3262–3267
  11. Dammacco F, Silvestris F, Castoldi B. The effectiveness and tolerability of of epoietin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res. 1998;28:127–134
  12. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinantv human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma. A randomized multi-center study. Blood. 1996;87:2675–2682
  13. Siedenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001;93:1204–1214
  14. Bohlius J, Wilson J, Seidelfeld J, et al. Recombinant human erythropoietin in cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708–714
  15. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23:5960–5972
  16. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  17. Wright JR, Yng YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25:1027–1032
  18. Goldberg P. Danish researchers post long-awaited Aranesp results – ever so discreetly. Cancer Lett. 2007;33:1–6
  19. Khuri FR. Weighting the hazards of erythropoiesis stimulation in patients with cancer. N Eng J Med. 2007;356:2445–2448
  20. Rizzo JD, Somerfield MR, Hagerty KL, et al. American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol. 2008;26:132–149
  21. Bohlius J, Schmidlin K, Schwarzer G, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532–1542
  22. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  23. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-b on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol. 2005;12:206–209
  24. Delarue R, Mounier Nm, Haioun C, et al. Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP 21: preliminary results of the LNH03-6B Randomized GELA Study. Blood. 2006;108;[abstr 2436]
  25. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo controlled trials. J Clin Oncol. 2005;23:6941–6948
  26. Smith RE, Aapro MS, Ludwig H, et al. Darbepoietin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy nor radiotherapy: results of a phase III multi-center, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26:1040–1050
  27. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol. 2002;20:2486–2494
  28. Food and Drug Administration Oncologic Drugs Advisory Committee. http://www.fda.gov/obrms/dockets/ac/04/briefing/4037b2.htm; 2004 [accessed 05.08].
  29. Engert M, Haverkamp H, Borchmann P, et al. A prospectively randomized placeb-controlled trial of epoetin – a in patients with advanced-stage Hodgkin lymphoma: final analysis of the GHSG HD-15-EPO trial. Haematologica. 2009;94(suppl. 2):[abst 1084]
  30. Shehata N, Walker I, Meyer R, et al. The use of erythropoiesis stimulating agents in patients with non-myeloid haematological malignancies: a systematic review. Ann Hematol. 2008;87:961–973
  31. San Miguel J, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Eng J Med. 2009;359:906–917
  32. Richardson P, Schlug R, Khuageva N, et al. ESAs do not adversely affect long-term outcomes nor increase the risk for thromboembolic events in multiple myeloma patients treated in the phase III VISTA trial. Blood. 2008;b12:[abstr 1741]
  33. Baz R, Walker E, Choueiri TK, et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol. 2007;117:162–167
  34. Katodritou E, Verrou E, Hadjiaggelidou C, et al. Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol. 2008;83:697–701
  35. Ludwig H, Anderson KC, Dammaco F, et al. ESAs not the culprit: more studies required. Am J Hematol. 2008;83:697–701
  36. Katodritou E, Verrou E, Zervas K. ESAs: not a convicted felon but still a suspect. Am J Hematol. 2008;83:880–881
  37. Steensma D. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol. 2008;83:693–694
  38. Glaspy J. Erythropoietin in cancer patients. Annu Rev Med. 2009;60:35.1–35.12
  39. Sinclair A, Todd M, Forthsythe K, et al. Expression and function of erythropoietin receptors in tumors. Cancer. 2007;110:477–488
  40. Huang J, Li CY, Mesa R, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer. 2008;112:2726–2732
  41. Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994;84:1056–1063
  42. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkins lymphoma: dose finding and identification of predictors of response. Blood. 1995;86:4446–4453
  43. Cazzola M, Ponchio L, Pedrotti C. Predictions of response to recombinant human erythropoietin in anemia of malignancy. Haematologica. 2006;81:434–441
  44. Littlewood T, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist. 2003;8:99–107
  45. Steinmetz T, Hellmich M, Neise M, et al. Prediction of responsiveness to treatment with erythropoiesis stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist. 2007;12:748–755
  46. Katodritou E, Terpos E, Zervas K, et al. Hypochorimic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic multiple myeloma and lymphoma patients. Ann Hematol. 2007;86:369–376
  47. Katodritou E, Speletas M, Zervas K, et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol. 2006;12:47–54
  48. Katodritou E, Ganz T, Terpos E, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables and anemia response. Am J Hematol. 2009;84:526
  49. Ukarma L, Johannes H, Beyer U, et al. Hepcidin as a predictor of response to epoietin in anemic cancer patients. Clin Chem. 2009;55:1354–1360
  50. Auerbach M, Ballard H, Trout , et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy related anemia: a multi-center, open-label, randomized trial. J Clin Oncol. 2004;22:1301–1307
  51. Hedenus M, Birgegard G, Nasman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative disorders. Leukemia. 2007;21:623–627
  52. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial for intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoietin alfa. J Clin Oncol. 2008;25:1619–1625
  53. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate improves response to epoietin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12:231–242
  54. Bastit L, Vandebroek A, Altintas S, et al. A randomized multi-center, controlled trial comparing the efficacy and safety of darbepoietin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol. 2008;25:1611–1618
  55. Bohlius J. Is intravenous iron with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?. Nat Clin Pract Oncol. 2008;12:688–689
  56. Katodritou E, Zervas K, Terpos E, Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol. 2008;142:3–10
  57. Katodritou E, Verrou E, Zervas K. Intravenous iron: a useful therapeutic tool but not a panacea. Am J Hematol. 2008;83:521–523
  58. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000;37:93–130
  59. Bennett CL, Silver SM, Djulbecovic B, et al. Venous thromboembolism and mortality associated with recombinant human erythropoietin and darbepoietin administration for the treatment of cancer-related anemia. Jama. 2008;299:914–924
  60. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoietin beta on survival, tumor progression and thromboembolic events in patients with cancer: an up-dated meta-analysis of 12 randomised controlledstidies including 2301 patients. Br J Cancer. 2008;99:14–22
  61. Agency of Healthcare Research and Quality. Comparative effectiveness of of epoietin and darbepoietin for managing anemia in patients undergoing cancer treatment. http://effectivehealthcare.ahrq.gov/>;.2006. [accessed 23.05.06].
  62. Background Information of Oncologic Drugs Advisory Committee Meeting. Information package 55;. <http://www.fda.gov>.
  63. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008;13:11–15
  64. Dahl N, Henry D, Coyne D. Thrombosis with erythropoiesis stimulating agents – does iron-deficient erythropoiesis play a role?. Sem Dial. 2008;21:210–211
  65. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thrombormbolism in a prospective observational study. Cancer. 2005;104:2822–2829
  66. Franchini M, Targher G, Montagnana M, et al. Iron and thrombosis. Ann Hematol. 2008;87:173–176
  67. Littlewood TJ, Bajetta E, Nortier JW, et al. Epoetin alfa study group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy. Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  68. Bell D, Grimes D, Gurney H, et al. Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Intern Med J. 2008;38:751–757
  69. Dammacco F, Castoldi G, Roedjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172–179
  70. Hedenus M, Adriansson M, Miguel JS, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394–403
  71. Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, et al. Quality of life and health benefits early treatment of mild anemia. Cancer. 2006;107:1907–1909
  72. Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessment in clinical trials. Qual Life Res. 1996;5:496–502
  73. Borg S, Glenngård AH, Osterborg A, et al. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. Acta Oncol. 2008;47:1009–1017
  74. Repetto L, Moeremans K, Annemans L. European guidelines for the management of chemotherapy induced anaemia and health economic aspects of treatment. Cancer Treat Rev. 2006;32:5–9
  75. Wilson J, Yao GL, Raftery J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;13:1–202[iii–iv]
  76. Duh MS, Weiner JR, White LA, et al. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. Pharmacoeconomics. 2008;26:99–120
  77. Norum J, Moen MA. Practice and costs of red blood cell (RBC) transfusion in an oncological unit. Anticancer Res. 2008;28:459–464

PII: S0305-7372(09)00117-0

doi: 10.1016/j.ctrv.2009.08.002

Cancer Treatment Reviews
Volume 35, Issue 8 , Pages 738-743 , December 2009

Article Tools